81503129, No. Pharmacological Action, Clinical Application and Adverse Reactions of Houttuynia Cordata. It was found that the total effective rate of LHQW granules combined with abidor treatment (LHQW group) was significantly higher than that of abidor group (80.95 % vs 64.86 %), while the rate of severe illness was markedly lower (14.29 % vs 23.65 %) [44]. Evid. The COVID-19 pneumonia epidemic has spread across the globe poses a significant challenge to public health worldwide. Heterogeneity was evaluated using I2 statistic. Case reports, unrelated studies, those with duplicate data, reviews, commentaries and animal-based studies were excluded from the current meta-analysis. There was no statistically significant difference in the incidence of adverse reactions during treatment of other diseases between the LHQW group and the conventional drug group (RR = 0.95, 95% CI = 0.651.39, p = 0.780). FIGURE 2. 37 studies reported adverse reactions of skin and its appendage damage. Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. It may benefit the treatment of COVID-19 by the signaling pathways such as advanced glycation end products (AGE)-receptor of AGE (RAGE), TNF, sarcoma-associated herpesvirus infection, IL-17 and human cytomegalovirus infection [41]. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). Li J.Y., You Z., Wang Q., Zhou Z.J., Qiu Y., Luo R., Ge X.Y. Considerable research to date has focused on the clinical efficacy of LHQW, the safety of LHQW is additionally an important consideration for clinical application that should not be neglected. Res. Other related clinical studies also revealed that LHQW significantly improved the symptoms in COVID-19 patients and reduced the duration of fever, fatigue and cough and so forth, which provide preliminary research evidence for clinical treatment of COVID-19 [45,46]. 13:764774. doi: 10.3389/fphar.2022.764774. The serious attack of Coronavirus Disease 2019 (COVID-19), infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has quickly spread around the globe [[1], [2], [3]]. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. 43 studies on treatment of respiratory tract infection were examined, with 29 reporting adverse reactions. Assoc. [14] Retraction Watch also notes that author Jia Zheng-hua is the son-in-law of Wu Yi-ling, the founder of the company in question. There was no statistically significant difference in the incidence of psychiatric disorders between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.253.97, p = 1.000). Analysis of Clinical Application and Adverse Reactions of Houttuynia Cordata Injection. A systematic review on the efficacy of Traditional Chinese Medicine on influenza. Federal government websites often end in .gov or .mil. Inclusion in an NLM database does not imply endorsement of, or agreement with, There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). Adv. Experimental study on prevention and treatment of influenza virus FM1 infection in mice by Lianhua Qingwen capsule. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. doi:10.3969/j.issn.1672-2809.2020.13.020, Liu, C. Y., Li, X. Q., and Cai, S. Q. Nevertheless, there are also potential limitations that need to be improved for future challenges. Drug-Use Hospitals China. (Yuxingcao), Pogostemon cablin (Blanco) Benth. 25 (4), 727790728729. Are there any known contraindications? Lv R.B., Wang W.J., Li X. doi:10.1016/0197-2456(86)90046-2, Duval, S., and Tweedie, R. (2000). Formulae. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. Inhibitorv Effect of Lianhua Oingwen Water Extract on Methicillin-Resistant staphylococcus Aureus Biofilm In Vitro. LHQW had been proven to accelerate the improvement of acute exacerbation of COPD (AECOPD) patients, especially for the high-risk subgroup, due to the decreased release of inflammatory mediators including IL-8, TNF- , IL-17, and IL-23 [38]. Plants of the World Online. The incidence of adverse reactions during treatment of influenza A (H1N1) was lower in the LHQW group compared to the conventional drug group (RR = 0.21, 95% CI = 0.130.36, p < 0.001). In addition to western medicine, the potential adverse drug reactions (ADRs) can not be ignored. Wu, L., Chen, Y., Ma, Y., Yang, Z., Yang, N., Deng, W., et al. For drowsiness of nervous system damage, sample size (p = 0.500), year of publication (p = 0.157), and treatment of the control group (p = 0.599) were not linked with heterogeneity. Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. Results: In total, 217 experimental studies were included. (2021). 2020, 3196375. doi:10.1155/2020/3196375, Yao, K. T., Liu, M. Y., Li, X., Huang, J. H., and Cai, H. B. (2020). The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). To protect the interests of patients, the risk-benefit ratio of the drug needs to be considered in clinical applications. It was demonstrated that the use of LHQW also brought the incidence of gastrointestinal reactions, as well as skin and its accessories injuries, including diarrhea, abdominal distension, gastrointestinal discomfort, rash, and itching, despite the low quality of the included documents [50,51]. Several limitations of our meta-analysis should be taken into consideration. Chin. official website and that any information you provide is encrypted J. Pharmacovigilance. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G.PRISMA Group (2009). Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. Li H.R., Chang L.P., Wei C., Jia Z.H. Control. Besides, in view of the definite effects of LHQW in preventing severe viral infections such as SARS and COVID-19 [17,44,45,49,52,53], LHQW may represent a considerable and effective strategy against unknown viral epidemics. Chin. Lianhua Qingwen Capsules has a better therapeutic effect on viral influenza, but the incidence of adverse reactions is high, and its safety must be taken seriously. 13 (08), 676681. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Cheng D.Z., Li Y. Therefore, studies with blinded participants and personnel and blinded outcome assessments were classified as low risk of bias. In terms of incomplete outcome data and selective reporting, the majority of studies reported complete data on all symptom indicators with a low risk of attrition and reporting bias. The sensitivity results are shown in Table 2. No use, distribution or reproduction is permitted which does not comply with these terms. LHQW capsules also showed a multi-access effects on anti-human influenza A virus H3N2, including the prevention effect on virus adsorption, inhibition on virus proliferation after adsorption and direct killing of the virus [25]. Here, we performed a meta-analysis of 217 Chinese experimental studies to evaluate the safety of LHQW. Common side effects are heart palpitations, nausea, and vomiting. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. (2021). doi:10.1142/S0192415X20500378. Experiments on animals using a combination of LHQW and oseltamivir to treat influenza B virus infections showed a potential inhibitory effect on overexpression of TNF-, MIP-1, RANTES, IFN-, IL-6, IL-8, IP-10, and MCP-1 at the mRNA level, and consequent prevented of the development of severe inflammatory reactions (Yang et al., 2020). Med. Chin. Bras (1992). Twenty-six studies focused on treatment of common pneumonia, of which 23 reported adverse reactions. A multicenter retrospective study showed similar results, which revealed that combined application of LHQW granules (6g, tid) could notably improve the clinical symptoms of fever, fatigue, cough, expectoration, chest tightness, and anorexia, and reduce the proportion of common to severe cases in COVID-19 patients with common type [20]. COPD is characterized by a chronic inflammatory response and can be worsened by acute exacerbations. Wang, Y., Greenhalgh, T., and Wardle, J. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. No adverse treatment-related effects were reported in all the included publications (from 2009 to 2011). However, no statistical difference was detected with regard to rash (RR = 0.60, 95% CI = 0.211.67) and dizziness (RR = 1.79, 95% CI = 0.339.74). 382 (21), e68. LHQW was initially approved by the China Food and Drug Administration (CFDA) in 2004 and represents the first traditional Chinese medicine that passed the rapid drug approval channel of CFDA for treatment of severe acute respiratory syndrome (SARS). Comprehensive analysis of influenza may provide a significant advantage in generalization of the conclusions. This study provides a basis for establishing the clinical safety profile of LHQW. A multi-center, randomized, double-blind, and placebo-controlled phase II clinical study, sponsored by Yiling Pharmaceutical Inc., was conducted to investigate the safety and efficacy of two doses of LHQW capsule compared to placebo in subjects with acute uncomplicated influenza in the U.S.A (https://www.clinicaltrials.gov/ct2/show/study/{"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}NCT02867358). Clinical effectiveness and case analysis in 54 NCP patients treated with Lanhuaqingwen granules. Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. An official website of the United States government. Pharmacopoeia of Peoples Republic of China. The Plant List (2021). There was no statistically significant difference in the incidence of adverse reactions during treatment of herpes zoster between the LHQW group and the conventional drug group (RR = 0.80, 95% CI = 0.521.23, p = 0.302). Zhou X.P. Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. Med. Drafting of the manuscript was done by CH and BH. Since the adverse reactions of LHQW are relatively minor, these functional changes can be recovered. Drug Related Hospital Admissions: the Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. Ling X.Y., Tao J.L., Sun X., Yuan B. ACE2, angiotensin-converting enzyme 2; ADRs, adverse drug reactions; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; AGE, advanced glycation end products; ALI, acute lung injury; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 19; EC50, median effective concentrations; HPLC, high performance liquid chromatography; IBV, influenza B virus; IFN, interferon; IL, interleukin; LHQW, Lianhua Qingwen; LPS, lipopolysaccharide; IP, interferon-inducible protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NF-B, nuclear factor-kappa B; RAGE, receptor of advanced glycation end products; SARS, Severe Acute Respiratory Syndrome; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TCM, traditional Chinese medicine; UPLC-DAD-QTOF-MS, ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry, Coronavirus, SARS-CoV-2, Lianhua Qingwen, Antiviral activity, Complementary strategy, {"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}. Traditional Chinese medicine formulation used for the treatment of influenza, Uses and controversies of Lianhua Qingwen in relation to COVID-19, by region, "How traditional Chinese medicine TCM is used to treat Covid-19", "The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule", "Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules", "Traditional Chinese cures battle for acceptance in COVID-19 fight", "Chinese traditional medicine for Covid-19 becomes money tree", "Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis", "Doctors warn against claims that Beijing-touted health supplement distributed in Canada treats COVID-19", "The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis", "Beijing pushes traditional Chinese medicine as coronavirus treatment", "China Covid-19 tsar pushed treatments without revealing business ties", "Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial", "Prominent Chinese scientist failed to disclose company ties in COVID-19 clinical trial paper", "DOH and FDA Clarify Claims on the Approval of Potential COVID-19 Treatments and Calls for Resignation of the SoH", "Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats symptoms, not COVID", "HSA Advisory on Lianhua Qingwen Products for Prevention or Treatment of COVID-19", "Fraudulent Coronavirus Disease 2019 (COVID-19) Products", "Chinese medicine Lianhua Qingwen makes its way into community for COVID-19 treatment despite Australian ban", https://en.wikipedia.org/w/index.php?title=Lianhua_Qingwen&oldid=1143380058, Short description is different from Wikidata, Articles needing expert attention from January 2023, Medicine articles needing expert attention, Articles containing simplified Chinese-language text, Articles containing traditional Chinese-language text, Articles with unsourced statements from August 2022, Creative Commons Attribution-ShareAlike License 3.0, Treatment against various respiratory diseases including, This page was last edited on 7 March 2023, at 11:01. Materia Med. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Alternat Med. Retrospective Clinical Analysis on Treatment of Novel Coronavirus-Infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen. Publication bias data are shown in Table 2 and the Funnel plot of pooled studies presented in Figure 3. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. doi:10.11816/cn.ni.2015-134443. Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. There was no statistically significant difference in the incidence of heart rate and arrhythmia between the LHQW group and the conventional drug group (RR = 0.67, 95% CI = 0.231.93, p = 0.454). Front. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Anti-viral effects of Lianhua Qingwen capsule against influenza A virus. doi:10.13422/j.cnki.syfjx.20201099, Ye, C., Gao, M., Lin, W., Yu, K., Li, P., and Chen, G. (2020). Ping F., Li Z., Zhang F., Li D., Han S. Effects of Lianhua Qingwen on pulmonary oxidative lesions induced by fine particulates (PM2.5) in rats. [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). Ther. Study on the network pharmacology and evidences of Lianhua Qingwen in the treatment of Novel Coronavirus (2019 nCoV) Pneumonia. Chinese Pharmacopoeia (2020). Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. Some notable dangerous reactions include heart attacks, strokes, seizures, and sudden deaths. (Guanghuoxiang), Rheum palmatum L. (Dahuang), Rhodiola rosea Linn. (2020). Therefore, it is essential to perform a systematic review and meta-analysis to assess the effect of Lianhua Qingwen combined with conventional antiviral Western Medicine in clinical treatment of COVID-19 or asymptomatic infection. As COVID-19 has led to serious death and lacks treatment strategies, the potential therapeutic drugs are increasingly being explored. A number of advantages of our study should additionally be mentioned. Data analysis were done by CH and DZ. However, since subgroup and sensitivity analyses did not explore the source of heterogeneity, we utilized meta-regression to determine the potential underlying factors. COVID-19 pandemic has caused a serious threat to public health and become the greatest challenge facing the world. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. (Hongjingtian), Mentha haplocalyx Briq. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. The following terms were searched using the title, abstract or keywords in the English databases: Lianhuaqinwen granule, Lianhuaqinwen capsule, Lianhua Qingwen capsule/granule. For the Chinese databases, the search terms used were: , , /.. Till August 8, 2020, over 19,000,000 people have been confirmed infected and more than 700,000 people have died during this severe viral prevalence. Wang X., Ding Y.Q. School of Pharmacy, Faculty of Life Sciences, University College London, United Kingdom. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. doi:10.1126/science.367.6485.1412, Lei, X. (2016). Accessibility [15], In the Philippines, its Food and Drug Administration approved Lianhua Qingwen on 7 August 2020 as a traditional herbal product that helps remove "heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose". Results were reported as risk ratio (RR) with 95% confidence interval (CI). LHQW has been recommended by the China International Exchange and Promotive Association for Medical and Health Care and the Chinese Research Hospital Association as comprehensive treatment for moderate or chronic COVID-19 pneumonia in conjunction with routine therapy (Jin et al., 2020). doi:10.1056/NEJMc2008043, Cao, L. J. Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza. Subgroup analysis additionally demonstrated LHQW group has a reduced incidence of rash, nausea or vomiting, and resurgence of disease. (2015). Anal. 228 (2), 8390. J. Eval. [citation needed]. Study supervision and funding were done by GZ. Zhao P., Yang H.Z., Lv H.Y., Wei Z.M. Further evaluation revealed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced pro-inflammatory cytokines (TNF-, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production and resulted in abnormal particle morphology of virion in cells [30]. (2010). 04:26. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. Further clinical trial showed that LHQW was superior to oseltamivir in improving the symptoms of influenza A virus infection by a meta-analysis of randomized, controlled trials [37]. Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy.
Meat Restaurant Toms River Real Housewives,
Dr Josephine Thinwa,
Articles L